Abilita Therapeutics

8 articles about Abilita Therapeutics

• Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer

  6/1/2023

  Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.

• Abilita Bio Appoints Dan Bradbury to its Newly Formed Board of Directors

  2/23/2022

  Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors.

• Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets

  8/24/2021

   Abveris, Inc. ("Abveris") and Abilita Bio, Inc. announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment.

• Abilita Bio Announces Business Growth and Key DevelopmentsShift to discovery of proprietary programs facilitated by increased resources, infrastructure and capabilities

  1/9/2020

  Abilita Bio, Inc., an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, today announced a series of corporate updates that includes an expansion of scientific scope, personnel, and infrastructure.

• Abilita Bio and Amgen Enter Into a Multi-Target Collaboration

  2/13/2019

  Research collaboration will focus on the generation of novel Enabled Membrane Proteins (EMPs™) to support R&D efforts on challenging drug targets

• X-Chem and Abilita Bio Announce a Joint Research Collaboration

  12/13/2017

  Under the terms of the agreement, Abilita will generate EMPs for several high-value GPCR and ion-channel targets, which will be screened by X-Chem using its proprietary DEX libraries to identify agonists and/or antagonists, as dictated by the target biology and desired mechanism of action.

• Abilita Bio Signs A New Research Collaboration With A Global Pharmaceutical Company And 2016 Milestone Review

  1/31/2017

• Abilita Bio Awarded NCI Phase-I SBIR Grant To Develop Therapeutic Antibodies Targeting Metastatic Breast Cancer

  9/20/2016